title: Effects of hemoperfusion in the treatment of childhood Henoch-Schönlein purpura nephritis.
abstract: OBJECTIVE
  Immune mediators play a role in the pathogenesis of Henoch-Schönlein purpura (HSP) nephritis. Since hemoperfusion (HP) is able to eliminate the immune mediators in many diseases, we investigated the effects of HP in the treatment of HSP nephritis.
  
  
  METHODS
  90 children with HSP nephritis were enrolled and followed up for 12 months. They were assigned to the HP group or the control group, respectively. Both groups were treated with corticosteroids and other supportive therapy. Patients in the HP group received HP for 3 consecutive days. The major outcomes included the percentage of patients with HSP nephritis, extrarenal symptoms, and recurrences and changes in serum levels of immune mediators.
  
  
  RESULTS
  The percentage of patients with nephritis in the HP group was less than that in the control group at each visit; the differences for prortions at 1, 3, 6, 12 months were 16.7% (p = 0.133), 31.3% (p = 0.004), 10.8% (p = 0.283), and 20.6% (p = 0.003), respectively. The severity and duration of abdominal and joint pains in the acute phase were significantly improved in the HP group compared to those in the control group. Hemoperfusion also significantly reduced patients' serum levels of immune mediators including IgA, TNF-α, IL-6, and LTB4. However, recurrences between the two groups were not significantly different.
  
  
  CONCLUSIONS
  Hemoperfusion in combination with corticosteroid was more effective than corticosteroid alone in treating HSP nephritis. The effects may be achieved by eliminating immune mediators.
authors: Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
authors: Lina
authors: L
authors: Chen
authors: Zheng
authors: Z
authors: Wang
authors: Songhui
authors: S
authors: Zhai
authors: Hui
authors: H
authors: Zhang
authors: Jing
authors: J
authors: Lu
authors: Xiuying
authors: X
authors: Chen
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000367:Age Factors; D015415:Biomarkers / Q000097:blood; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006464:Hemoperfusion / Q000009:adverse effects; D006801:Humans; D011695:IgA Vasculitis / Q000097:blood / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018836:Inflammation Mediators / Q000097:blood; D053208:Kaplan-Meier Estimate; D008297:Male; D009393:Nephritis / Q000097:blood / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D012008:Recurrence; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D015415:Biomarkers; D007166:Immunosuppressive Agents; D018836:Inflammation Mediators